A Phase 2 trial (NCT00433446) examining siltuximab (CNTO328), an anti-IL6 antibody, showed siltuximab did not have clinical benefit for patients with advanced prostate cancer (Dorff et al., 2010). Here, IL6 is linked to prostate carcinoma.